ATC code A05

ATC code A05 Bile and liver therapy is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.^[1]^[2]^[3] Subgroup A05 is part of the anatomical group A Alimentary tract and metabolism.^[4]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QA05.^[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

A05A Bile therapy

A05B Liver therapy, lipotropics

A05BA Liver therapy

A05BA01 Arginine glutamate

A05BA03 Silymarin

A05BA04 Citiolone

A05BA05 Epomediol

A05BA06 Ornithine oxoglutarate

A05BA07 Tidiacic arginine

A05BA08 Glycyrrhizic acid (glycyrrhizin)

A05BA09 Metadoxine

A05BA10 Phospholipids

QA05BA90 Methionine

A05C Drugs for bile therapy and lipotropics in combination

Empty group

References

^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
^ "ATC/DDD Index 2022: code A05". WHO Collaborating Centre for Drug Statistics Methodology.
^ "ATCvet Index 2022: code QA05". WHO Collaborating Centre for Drug Statistics Methodology.

[1] "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.

[2] World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.

[3] "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.

[4] "ATC/DDD Index 2022: code A05". WHO Collaborating Centre for Drug Statistics Methodology.

[5] "ATCvet Index 2022: code QA05". WHO Collaborating Centre for Drug Statistics Methodology.

[1]

[2]

[3]

[4]

[5]

v t e Bile and liver therapy (A05)
Bile therapy	bile acid Chenodeoxycholic acid Cholic acid Obeticholic acid Ursodeoxycholic acid Ursodoxicoltaurine Cyclobutyrol Elafibranor Hymecromone Maralixibat chloride Menbutone Nicotinyl methylamide Odevixibat Piprozolin Seladelpar
Liver therapy	Arginine glutamate Citiolone Epomediol Glycyrrhizin Metadoxine Methionine Ornithine oxoglutarate Phospholipids Silymarin Tidiacic arginine

ATC code A: Alimentary tract and metabolism
A01 Stomatological preparations A02 Drugs for acid related disorders A03 Drugs for functional gastrointestinal disorders A04 Antiemetics and antinauseants A05 Bile and liver therapy A06 Drugs for constipation A07 Antidiarrheals, intestinal anti-inflammatory/anti-infective agents A08 Antiobesity preparations, excluding diet products A09 Digestives, including enzymes A10 Drugs used in diabetes A11 Vitamins A12 Mineral supplements A13 Tonics A14 Anabolic agents for systemic use A15 Appetite stimulants A16 Other alimentary tract and metabolism products
Other ATC codes
A B C D G H QI J L M N P R S V

A05A Bile therapy

A05AA Bile acids and derivatives

A05AB Preparations for biliary tract therapy

A05AX Other drugs for bile therapy

A05B Liver therapy, lipotropics

A05BA Liver therapy

A05C Drugs for bile therapy and lipotropics in combination

References